Omkar Speciality Chemicals Limited: Post-CIRP Update

Omkar Speciality Chemicals Limited has outlined its post-Corporate Insolvency Resolution Process (CIRP) financial results and governance updates. The company has seen significant changes in its leadership and operational framework.

Reader Takeaway: New management and capital infusion signal revival, but zero revenue and ongoing losses pose challenges.

What just happened

The National Company Law Tribunal (NCLT) approved Omkar Speciality Chemicals' resolution plan on July 31, 2025. Subsequently, the company appointed Mr. Dipak Kumar Shaw as Chief Executive Officer and Mr. Ruhini Kumar Chakraborty as Independent Director. The Audit and Stakeholders' Relationship committees have been constituted. A new current bank account has been approved with ICICI Bank.

Why this matters

This marks a crucial transition phase for Omkar Speciality Chemicals as it aims to revive operations after insolvency. The NCLT approval provides a clear path forward, while new leadership and governance structures are critical for rebuilding investor confidence and ensuring compliance.

The backstory

Omkar Speciality Chemicals underwent the CIRP, a process for reviving stressed companies. The resolution plan, approved by the NCLT, involves a total resolution amount of ₹26.65 crore, with ₹23.14 crore allocated for creditors and ₹3.51 crore for capex and working capital. A key aspect is the infusion of ₹15.0816 crore by the Resolution Applicant.

What changes now

With the resolution plan in place and new leadership appointed, the focus shifts to operational revival. The company has also appointed statutory and secretarial auditors for FY 2025-26. The constitution of board committees and the opening of a new bank account are steps towards re-establishing normal business functions.

Risks to watch

The company's financial performance for the nine months ended December 31, 2025, shows a net loss of ₹1.2562 crore. Critically, total income from operations was ₹0.0082 crore for the quarter ended December 31, 2025, indicating a complete absence of revenue from core business activities. This continued lack of operating revenue and the negative net worth present significant challenges.

Peer comparison

Companies emerging from CIRP typically face a period of rebuilding. While specific peer performance varies, the immediate challenge for Omkar Speciality Chemicals is to generate operating revenue and move towards profitability, a common hurdle for entities in similar recovery phases.

Context metrics (time-bound)

• Resolution Plan Approval: NCLT approval on July 31, 2025.
• Fund Infusion: ₹15.0816 crore by Resolution Applicant.
• Total Resolution Amount: ₹26.65 crore.
• Payment to Creditors: ₹23.14 crore.
• Net Loss (9M ended Dec 2025): ₹-1.2562 crore.
• Total Income (Q3 FY26): ₹0.0082 crore.

What to track next

Investors will be closely watching for signs of operational revival, including the generation of consistent operating revenue. The effectiveness of the new management team in turning around the business and stabilizing its financial position will be critical indicators.